Farallon Capital Management LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
Farallon Capital Management LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
Farallon Capital Management LLC increased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 67.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,356,987 shares of the biotechnology company's stock after buying an additional 545,240 shares during the period. Farallon Capital Management LLC's holdings in Blueprint Medicines were worth $86,684,000 as of its most recent filing with the Securities and Exchange Commission.
据Blueprint Medicines Co.(纳斯达克代码:BPMC-GET Rating)在最近提交给美国证券交易委员会的信息中称,Farallon Capital Management LLC在第一季度增持了该公司67.2%的股份。该机构投资者持有这家生物技术公司1,356,987股股票,在此期间又购买了545,240股。截至最近提交给美国证券交易委员会(Securities And Exchange Commission)的文件,Farallon Capital Management LLC持有的Blueprint Medicines价值86,68.4万美元。
Other institutional investors have also recently added to or reduced their stakes in the company. Duality Advisers LP purchased a new stake in Blueprint Medicines during the first quarter worth about $761,000. JPMorgan Chase & Co. lifted its holdings in shares of Blueprint Medicines by 1.9% in the first quarter. JPMorgan Chase & Co. now owns 1,675,124 shares of the biotechnology company's stock valued at $107,006,000 after purchasing an additional 30,963 shares in the last quarter. Aigen Investment Management LP purchased a new stake in shares of Blueprint Medicines in the first quarter valued at about $570,000. Alliancebernstein L.P. lifted its holdings in shares of Blueprint Medicines by 7.6% in the fourth quarter. Alliancebernstein L.P. now owns 1,500,745 shares of the biotechnology company's stock valued at $160,745,000 after purchasing an additional 106,541 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of Blueprint Medicines by 12.6% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 352,243 shares of the biotechnology company's stock valued at $37,728,000 after purchasing an additional 39,293 shares in the last quarter.
其他机构投资者最近也增持或减持了该公司的股份。Duality Advisers LP在第一季度购买了Blueprint Medicines的新股份,价值约761,000美元。摩根大通第一季度增持Blueprint Medicines股票1.9%。摩根大通目前持有这家生物技术公司1,675,124股股票,价值107,006,000美元,此前该公司在上个季度又购买了30,963股。Aigen Investment Management LP在第一季度购买了Blueprint Medicines的新股份,价值约57万美元。联合伯恩斯坦公司在第四季度增持了Blueprint Medicines 7.6%的股票。联合伯恩斯坦公司现在拥有这家生物技术公司1,500,745股股票,价值160,745,000美元,上个季度又购买了106,541股。最后,Candriam卢森堡S.C.A.在第四季度增持了Blueprint Medicines 12.6%的股票。Candriam卢森堡股份有限公司现在持有这家生物技术公司352,243股,价值37,728,000美元,在上个季度又购买了39,293股。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several analysts have issued reports on the stock. The Goldman Sachs Group upped their price target on shares of Blueprint Medicines from $126.00 to $143.00 and gave the company a "buy" rating in a report on Wednesday, August 3rd. Piper Sandler reduced their price target on shares of Blueprint Medicines from $65.00 to $59.00 in a report on Tuesday, August 2nd. Morgan Stanley upped their price target on shares of Blueprint Medicines from $65.00 to $80.00 and gave the company an "equal weight" rating in a report on Friday. Credit Suisse Group upped their price target on shares of Blueprint Medicines from $80.00 to $90.00 in a report on Wednesday, September 7th. Finally, Raymond James reduced their price objective on shares of Blueprint Medicines from $133.00 to $115.00 and set a "strong-buy" rating on the stock in a research note on Wednesday, August 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Blueprint Medicines has a consensus rating of "Moderate Buy" and a consensus price target of $92.19.
几位分析师已经发布了关于该股的报告。在8月3日星期三的一份报告中,高盛夫妇将Blueprint Medicines的目标价从126.00美元上调至143.00美元,并给予该公司“买入”评级。派珀·桑德勒在8月2日星期二的一份报告中将Blueprint Medicines的股票目标价从65.00美元下调至59.00美元。在周五的一份报告中,摩根士丹利将蓝图医药的目标价从65.00美元上调至80.00美元,并给予该公司“同等权重”的评级。瑞士信贷集团在9月7日星期三的一份报告中将Blueprint Medicines的股票目标价从80.00美元上调至90.00美元。最后,雷蒙德·詹姆斯将Blueprint Medicines股票的目标价从133.00美元下调至115.00美元,并在8月3日星期三的一份研究报告中对该股设定了“强力买入”评级。两位投资分析师对该股的评级为卖出,四位给予持有评级,七位给予买入评级,一位给予该公司股票强势买入评级。根据MarketBeat的数据,Blueprint Medicines的共识评级为“适度买入”,共识目标价为92.19美元。
Insider Buying and Selling
内幕买卖
Blueprint Medicines Stock Performance
蓝图药品类股表现
Shares of BPMC stock opened at $75.47 on Tuesday. Blueprint Medicines Co. has a one year low of $43.46 and a one year high of $117.86. The company has a 50 day moving average price of $63.57 and a 200 day moving average price of $60.69. The firm has a market capitalization of $4.50 billion, a price-to-earnings ratio of -6.36 and a beta of 0.78.
周二,BPMC股票开盘报75.47美元。Blueprint Medicines Co.的一年低点为43.46美元,一年高位为117.86美元。该公司的50日移动均线价格为63.57美元,200日移动均线价格为60.69美元。该公司的市值为45亿美元,市盈率为-6.36倍,贝塔系数为0.78。
Blueprint Medicines (NASDAQ:BPMC – Get Rating) last issued its quarterly earnings results on Tuesday, August 2nd. The biotechnology company reported ($2.68) EPS for the quarter, missing the consensus estimate of ($2.23) by ($0.45). Blueprint Medicines had a negative return on equity of 45.89% and a negative net margin of 304.41%. The company had revenue of $36.55 million for the quarter, compared to analyst estimates of $37.61 million. During the same period last year, the company posted ($1.86) EPS. The business's revenue for the quarter was up 33.9% on a year-over-year basis. As a group, equities analysts forecast that Blueprint Medicines Co. will post -9.2 EPS for the current fiscal year.
Blueprint Medicines(纳斯达克代码:BPMC-GET Rating)最近一次发布季度收益报告是在8月2日,星期二。这家生物技术公司公布了本季度每股收益(2.68美元),低于普遍预期的(2.23美元)和(0.45美元)。Blueprint Medicines的净资产回报率为负45.89%,净利润率为负304.41%。该公司本季度营收为3,655万美元,而分析师预期为3,761万美元。去年同期,该公司公布的每股收益为1.86美元。该业务当季营收较上年同期增长33.9%。作为一个整体,股票分析师预计Blueprint Medicines Co.本财年每股收益将达到9.2欧元。
About Blueprint Medicines
关于蓝图药品公司
(Get Rating)
(获取评级)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.
BluePrint Medicines Corporation是一家精准治疗公司,在美国和国际上开发针对基因定义的癌症和血液疾病的药物。该公司正在开发用于治疗全身性肥大细胞增多症(SM)和胃肠道间质瘤的AYVAKIT;用于治疗非进展性肥大细胞增多症和其他肥大细胞疾病的口服可用、有效的试剂盒抑制剂BLU-263;以及用于治疗肝细胞癌的口服可用且有效的抑制剂Fisogatinib。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Blueprint Medicines (BPMC)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- 免费获取StockNews.com关于蓝图药物的研究报告(BPMC)
- 这些股息获得者值得在你的投资组合中占有一席之地吗?
- 达顿餐厅走低通胀之路
- 这3只股票为何在9月火爆开盘
- 通货膨胀没有差别,但它的影响有差别
- 3只被降级的必备股票放在你的观察名单上
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating).
想看看其他对冲基金持有BPMC的情况吗?访问HoldingsChannel.com获取Blueprint Medicines Co.(纳斯达克代码:BPMC-GET Rating)的最新13F申报文件和内幕交易信息。
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
接受蓝图药物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Blueprint Medicines和相关公司的最新新闻和分析师评级的每日摘要。